![]() Overview page represent trading in all U.S. Indexes: Index quotes may be real-time or delayed as per exchange requirements refer to time stamps for information on any delays. Copyright 2019© FactSet Research Systems Inc. Fundamental company data and analyst estimates provided by FactSet. International stock quotes are delayed as per exchange requirements. stock quotes reflect trades reported through Nasdaq only comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. Dividend Yield A company's dividend expressed as a percentage of its current stock price. Restricted stock typically is that issued to company insiders with limits on when it may be traded. To calculate, start with total shares outstanding and subtract the number of restricted shares. Public Float The number of shares in the hands of public investors and available to trade. Shares Outstanding Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public. For companies with multiple common share classes, market capitalization includes both classes. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. Market Capitalization Reflects the total market value of a company. Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Revenue is distributed geographically as follows: Ireland (1.7%), the United States (49.7%), the United Kingdom (20.5%) and other (28.1%).P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. management and operation of a platform for the exchange and outsourcing of group health insurance plans and medical benefits (14.7%): allowing employees and retirees to choose the health coverage that meets their needs Additionally, the group offers insurance and reinsurance consulting services, financial management services, financing and investment strategies, as well as actuarial studies and expertise in mergers and acquisitions, etc., while developing software solutions for modeling and analysis of risks and financial activities risk/return balance management consulting services (17.7%): for investors, insurers and reinsurers. The group is also developing an insurance brokerage activity development of enterprise risk management solutions and services (31.9%): risk analysis, assessment consulting, effective risk management and anticipation services, design and development of software solutions for risk management. human capital and social benefits consulting services (35.6%): consulting services in the organization, skills assessment, management and optimization of social benefits, compensation of executives and employees, etc. Revenues break down by activity as follows: Willis Towers Watson Public Limited Company is a world leader in consulting, insurance brokerage and risk management software development. Willis Towers Watson Public Limited Company Updates Earnings Guidance for Year 2024 Willis Towers Watson Public Limited Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 (WTW) WILLIS TOWERS WATSON Sees Fiscal Year 2024 EPS Range $15.40 - $17.00 Willis Towers Watson's Q2 Adjusted Earnings Slip, Revenue Increases Lowers 2024 Earnings Guidance Street Est of $2.33Įarnings Flash (WTW) WILLIS TOWERS WATSON Reports Q2 Revenue $2.16B, vs. Transcript : Willis Towers Watson Public Limited Company, Q2 2023 Earnings Call, Jul 27, 2023Įarnings Flash (WTW) WILLIS TOWERS WATSON Reports Q2 EPS $2.05, vs. Sector Update: Financial Stocks Gain Pre-Bell Thursday ![]() Tranche Update on Willis Towers Watson Public Limited Company's Equity Buyback Plan announced on November 5, 2007. Sector Update: Financial Stocks Declining Late Thursday Afternoon Raymond James Downgrades Willis Towers Watson to Outperform From Strong Buy, Adjusts Price Target to $260 From $270 Raymond James Adjusts Price Target on Willis Towers Watson to $250 From $260, Maintains Outperform Rating
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |